Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist, in Participants With Advanced Prostate Cancer

NCT04693507 is registered in ClinicalTrials.gov with Antev Ltd. as lead sponsor.

NCT NCT04693507
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04693507 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist, in Participants With Advanced Prostate Cancer
Lead sponsor
Antev Ltd.
Phase
Phase 2
Overall status
Completed
Start date
March 4, 2021
Completion date
February 6, 2023
Enrollment
50 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic adenoma